

Prothena Corp plc  
Form 8-K  
July 05, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 5, 2016**

**PROTHENA CORPORATION PUBLIC LIMITED COMPANY**

**(Exact Name of Registrant as Specified in its Charter)**

**Ireland**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-35676**  
**(Commission**

**File Number)**  
**Adelphi Plaza**

**98-111119**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: Prothena Corp plc - Form 8-K

**Upper George s Street, Dún Laoghaire**

**Co. Dublin, A96 T927**

**Ireland**

**(Address of principal executive offices including Zip Code)**

**Registrant s telephone number, including area code: 011-353-1-236-2500**

**(Former Name or Former Address, if Changed Since Last Report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On July 5, 2016, Prothena Corporation plc issued a press release announcing new clinical data from the Phase 1/2 dose-escalation and expansion study of NEOD001, an investigational monoclonal antibody for the potential treatment of AL amyloidosis. That press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated July 5, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 5, 2016

**PROTHENA CORPORATION PLC**

By: /s/ Tran B. Nguyen

Name: Tran B. Nguyen

Title: Chief Financial Officer